CDK/HDAC-IN-2_product_DataBase

Bioactivity	CDK/HDAC-IN-2 is a potent HDAC/CDK dual inhibitor with IC50 of 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM for HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, respectively. CDK/HDAC-IN-2 shows excellent antiproliferative activities. CDK/HDAC-IN-2 induces apoptosis and cell cycle arrest at G2/M phase. CDK/HDAC-IN-2 shows potent antitumor efficacy[1].
Invitro	CDK/HDAC-IN-2 (compound 7c) shows antiproliferative activity with IC50s of 0.71, 1.20, 1.83, 4.19, 7.76, 4.47 µM for HCT116, A375, Hela, H460, SMMC7721, NIH 3T3 cells, respectively[1].CDK/HDAC-IN-2 (24 h) shows anti-migration ability in A375 and H460 cells[1].CDK/HDAC-IN-2 (0.5, 1, 2 µM) induces apoptosis and cell cycle arrest at G2/M phase[1].CDK/HDAC-IN-2 accelerates intracellular ROS accumulation, leading to cancer cell death[1]. Cell Cycle Analysis[1] Cell Line:
Name	CDK/HDAC-IN-2
CAS	2580938-58-3
Formula	C25H20Cl2N6O3
Molar Mass	523.37
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

PeptideDB